The United Arab Emirates has strengthened its regulatory framework governing narcotic drugs and psychotropic substances through Federal Decree-Law No. 14 of 2025, which amended provisions of Federal Decree-Law No. 30 of 2021 on Combating Narcotic Drugs and Psychotropic Substances. Effective from 1 January 2026, the amendments increase criminal liability for the improper prescribing and dispensing of controlled substances, restructure the authorities responsible for narcotics and medical-product regulation, and expand the legal framework for addiction treatment and rehabilitation.
The reforms are particularly significant for doctors, pharmacists, pharmaceutical establishments and healthcare facilities. While the UAE continues to permit the legitimate medical use of controlled substances, the amended law imposes serious criminal consequences where such substances are prescribed or dispensed without the required legal or medical basis.
Existing Framework for Controlled Medicines
The UAE’s regulation of narcotic and psychotropic substances operates through a combination of the Narcotics Law and separate legislation governing medical products and pharmaceutical practice.
Federal Decree-Law No. 30 of 2021 establishes the overarching controls on the possession, handling, use, distribution and supply of narcotic drugs and psychotropic substances. Legitimate medical use is permitted, but only within the conditions prescribed by law and under the supervision of competent authorities.
This framework is complemented by Federal Decree-Law No. 38 of 2024 Governing Medical Products, Pharmacists and Pharmaceutical Establishments, which came into force on 2 January 2025. The law regulates pharmaceutical establishments and prescribes specific requirements for controlled prescriptions and their dispensing.
For example, Article 77 requires a pharmacist dispensing a pharmaceutical product containing a narcotic or psychotropic substance to verify that the prescription is issued through the prescribed electronic system, contains specified information regarding the medicine, dosage and patient, and complies with applicable limits. Article 81 further requires pharmacists to record prescriptions for controlled and semi-controlled substances on the national Narcotic and Psychotropic Substances Tracking Platform.
The 2025 amendment therefore operates alongside an existing system of prescription controls, licensing requirements and electronic monitoring. Its significance is that certain breaches of those controls now carry substantially greater criminal consequences.
Under the amended Narcotics Law, a pharmacy that dispenses a narcotic drug or psychotropic substance without a valid prescription or in quantities exceeding the approved limits may face imprisonment for not less than five years and a fine of not less than AED 50,000. The conduct is treated as an offence of facilitating the use of narcotic drugs.
The provision is significant because it moves beyond ordinary administrative or professional sanctions. Where the statutory conditions are satisfied, improper dispensing itself constitutes a criminal offence carrying a mandatory minimum custodial sentence.
The requirement for a valid prescription must also be read with the 2024 Medical Products Law. Pharmacists are not permitted simply to rely on the existence of a prescription. The prescription must satisfy prescribed formal and substantive requirements, including information concerning the active ingredient, quantity, dosage, method and duration of use, and patient identity. The prescribed dose must also remain within the limits established by the regulatory framework unless the relevant authority has authorised an exception.
This creates a compliance chain running from the issuing physician to the dispensing pharmacist and ultimately to the electronic tracking system.
Doctors Also Face Criminal Consequences
The reforms extend equivalent protection to the prescribing stage.
A physician who issues a prescription for a narcotic drug or psychotropic substance without the required licence, without medical justification, or in violation of approved limits may be punished by imprisonment for not less than five years and a fine of not less than AED 50,000. The conduct is likewise classified as facilitating narcotic drug use.
The provision establishes that a prescription for a controlled substance is not merely a matter of medical discretion. The prescribing decision must be supported by a lawful medical basis and remain within the limits established by the regulatory framework.
The 2024 Medical Products Law reinforces this position by regulating who may issue controlled prescriptions and restricting healthcare practitioners from prescribing controlled substances for themselves, their spouse or relatives up to the second degree.
The combined framework therefore places responsibility on both sides of the supply chain. A pharmacist cannot lawfully dispense a defective prescription, while a doctor cannot avoid responsibility where a prescription itself was issued outside the statutory requirements.
A Clearer Institutional Structure
The amendments also reorganise the UAE’s institutional approach to narcotics and medical-product regulation.
Federal Decree by Law No. 2 of 2025 established the National Drug Enforcement Authority (NDEA) as a federal authority reporting to the Cabinet. Effective from 1 January 2026, the NDEA replaced the General Department of Anti-Narcotics at the Ministry of Interior in relation to the relevant rights, obligations, assets and functions.
Separately, the Emirates Drug Establishment (EDE) assumes the central federal role in regulating medical products and pharmaceutical establishments under the 2024 medical-products framework. The 2025 narcotics amendment updates statutory references accordingly.
The division creates a clearer distinction between two related functions: regulation of medicines and pharmaceutical activity on the one hand, and national narcotics enforcement on the other. At the same time, the two areas remain closely connected because lawful access to controlled substances depends on both medical and enforcement controls.
Legitimate Medical and Scientific Use Remains Permitted
The stronger criminal provisions do not amount to a prohibition on narcotic or psychotropic substances in healthcare.
The law continues to permit authorised entities to possess and handle controlled substances for legitimate medical and scientific purposes. These include healthcare facilities, research centres, chemical testing laboratories, and establishments involved in the manufacture, storage and distribution of medical products, subject to the required licences and controls.
The legal distinction is therefore between authorised medical use and unlawful access or diversion. Controlled medicines remain essential for pain management, anaesthesia, psychiatric treatment and other medical purposes, but the legislation requires their movement through the healthcare system to remain traceable and properly authorised.
Expansion of Treatment and Rehabilitation
The reforms also introduce a significant treatment component.
Federal and local health authorities, as well as private health facilities, may establish specialised units for the treatment and rehabilitation of persons addicted to narcotic drugs or psychotropic substances. The UAE Cabinet is responsible for issuing the detailed regulations governing these facilities.
This is consistent with the broader structure of the 2021 Narcotics Law, which distinguishes between serious narcotics-related criminal activity and circumstances involving addiction that may require treatment.
The approach combines two objectives. Trafficking, unlawful distribution and misuse of controlled substances remain subject to strict criminal enforcement, while rehabilitation provides a mechanism to address dependency through medical intervention. The expansion of treatment capacity through private facilities is particularly significant because it broadens the institutional infrastructure available to individuals requiring specialised care.
Deportation of Foreign Nationals
The amended framework also strengthens the immigration consequences of narcotics convictions.
A foreign national convicted of a narcotics offence must generally be deported after completion of the sentence. The law, however, provides limited exceptions where the person is the spouse or first-degree relative of a UAE citizen at the time of the offence, or where deportation would cause serious harm to the stability of a UAE-resident family or deprive a family member of necessary care, subject to the statutory conditions.
Deportation therefore operates as an additional consequence of conviction rather than as a substitute for the criminal sentence.
Pharmacies should ensure that prescriptions are valid, electronically recorded where required, within permitted dosage and quantity limits, and accurately entered into the national tracking system. Doctors must ensure that controlled substances are prescribed within the scope of their licence, supported by medical justification and consistent with the applicable limits.
Healthcare facilities handling controlled substances for storage, research, manufacturing or treatment must similarly maintain the necessary licences and controls.
The consequences of failing to do so can now be severe. The minimum five-year custodial sentence and AED 50,000 fine underline the legislature’s approach to preventing diversion of controlled medicines from lawful medical channels.
Looking Ahead
The latest reforms demonstrate that the UAE’s narcotics policy is moving on two parallel tracks: stronger deterrence against unlawful access and diversion, combined with greater capacity for treatment and rehabilitation.
For healthcare providers, the most immediate concern is the increased criminal exposure associated with unlawful prescribing and dispensing. The reforms also underline the importance of documentation, prescription verification, electronic tracking and compliance with licensing requirements throughout the pharmaceutical supply chain.
At the institutional level, the establishment of the NDEA and the expanded regulatory role of the EDE provide a clearer framework for coordinating enforcement and medical-product oversight.
The practical position is therefore clear: controlled medicines remain legally available for legitimate healthcare and scientific purposes, but the route from prescription to dispensing is subject to increasingly strict statutory controls. For doctors, pharmacists and pharmaceutical establishments, compliance is no longer simply an administrative responsibility. In specified circumstances, a breach may result in criminal prosecution, imprisonment and significant fines.
Conclusion
Federal Decree-Law No. 14 of 2025 represents an important strengthening of the UAE’s narcotics regulatory framework. By imposing minimum criminal penalties for unlawful prescribing and dispensing, reorganising institutional responsibilities and expanding treatment infrastructure, the amendments reinforce both the enforcement and public-health dimensions of narcotics regulation.
The reforms also demonstrate a broader legislative approach: serious consequences for conduct that facilitates unlawful drug use, while preserving regulated access to controlled medicines and expanding pathways for addiction treatment.
As the amended framework operates alongside the UAE’s medical-products and pharmaceutical legislation, healthcare providers should review their prescribing, dispensing, record-keeping and internal compliance procedures to ensure that controlled substances remain within the boundaries prescribed by law.
Also See – Related Guidance for Travellers
These reforms also highlight the importance of understanding the UAE’s wider legal framework on drugs and controlled medicines. Our previous publications, “From Legal Overseas to Trouble in UAE: What Travellers Need to Know About Drug Consumption” and “Bringing Medicines into the UAE: A Legal Guide for Travellers,” provide further guidance on the rules applicable to travellers and individuals carrying controlled medication into the UAE.
These are better framed around the gaps around the law rather than repeating the penalties and institutional changes already covered:
References
Federal Decree-Law No 30 of 2021 on Combating Narcotic Drugs and Psychotropic Substances, as amended by Federal Decree-Law No 14 of 2025 https://uaelegislation.gov.ae/en/legislations/1540 accessed 7 September 2026.
Federal Decree-Law No 14 of 2025 Amending Certain Provisions of Federal Decree-Law No 30 of 2021 Concerning Combating Narcotic Drugs and Psychotropic Substances (Ministry of Health and Prevention, 2025) https://mohap.gov.ae/en/w/federal-decree-law-no.-14-of-2025 accessed 7 September 2026.
Can a patient legally challenge a pharmacist’s refusal to dispense a controlled medicine?
Yes, where the refusal is inconsistent with a valid prescription and the applicable regulatory requirements. However, pharmacists remain bound by their professional and statutory duties, and may lawfully refuse dispensing where the prescription is incomplete, outside permitted limits, or otherwise non-compliant. Disputes should therefore be assessed against both the prescription and the applicable dispensing rules.
Who is responsible when a controlled medicine is transferred between healthcare facilities?
Responsibility does not rest solely with the receiving facility. Transfers of narcotic and psychotropic medicines between government and private healthcare facilities, including emergency transfers, are subject to EDE approval and documentation requirements. These include details of the medicine, patient, prescription and medical report, as well as valid establishment and professional licences.
Can a pharmacy import controlled medicines directly from outside the UAE?
Yes, but only through the prescribed regulatory process. The importing pharmaceutical establishment must hold the relevant EDE licence and obtain an import authorisation, supported by documents including the product registration certificate, analysis certificate, invoice and customs clearance documentation.
Call Us Now
Schedule a free consultation for all your legal challenges
